What question did this study set out to answer?

To identify specific serum N-glycan alterations capable of accurately distinguishing prostate cancer from benign prostate hyperplasia and stratifying tumor aggressiveness.

September 22, 2010Glycobiology

Core fucosylation and 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia

View Full Paper

Ask AI

Bookmark

Authors

RSRadka SaldovaUniversity College Dublin YFYue FanShanghai Jiao Tong University JFJ. M. FitzpatrickUniversity College Dublin

Discussion

Member takes

Implication

Biomarker study reveals distinct serum N-glycan alterations distinguishing prostate cancer from benign hyperplasia, highlighting potential noninvasive diagnostic targets.

Key Points

To identify specific serum N-glycan alterations capable of accurately distinguishing prostate cancer from benign prostate hyperplasia and stratifying tumor aggressiveness.
Analyzed serum N-glycans across 13 benign prostate hyperplasia (BPH) samples and 34 prostate cancer samples (17 Gleason score 5 and 17 Gleason score 7).
Employed a fully quantitative high-throughput N-glycan analysis combined with exoglycosidase digestions on whole serum glycoproteins.
Levels of core-fucosylated biantennary glycans and α2-3-linked sialic acids significantly increased in prostate cancer relative to BPH.
Triantennary trigalactosylated glycans and tetraantennary tetrasialylated glycans with outer arm fucose significantly decreased, whereas tetraantennary tetrasialylated glycans increased in Gleason 7 compared with Gleason 5.
Identified glycan panels differentiated cancer from BPH and Gleason 7 from Gleason 5 more effectively than prostate-specific antigen, with specific glycan shifts correlating with perineural invasion.

Cite This Study

Saldova et al. (2010) studied this question.

synapsesocial.com/papers/6aa025f13ce5f043f590e8ec https://doi.org/10.1093/glycob/cwq147

View Full Paper

Ask AI

Bookmark

Implication

Biomarker study reveals distinct serum N-glycan alterations distinguishing prostate cancer from benign hyperplasia, highlighting potential noninvasive diagnostic targets.

Core fucosylation and 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia

Discussion

Member takes

Implication

Key Points

Cite This Study

Core fucosylation and 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider